Medical Devices & Healthcare Equipment Manufacturing
Strategic Profile
The company is positioned for rapid clinical adoption and global expansion, with the Swoop system expected to achieve outsized revenue growth, strong recurring high-margin revenue, and substantial operating margin improvements. Hyperfine recently obtained regulatory approval from India's Central Drugs Standard Control Organization in December 2025 and is planning commercial launches in India and other international markets.
Cyborg Score Rationale
Hyperfine demonstrates strong clinical validation and recent regulatory expansion into India, with record Q4 placements and next-generation product launches. However, the company remains pre-profitability with negative EBITDA of $38.74M and minimal trailing 12-month revenue of $10.6M, coupled with execution risks in scaling commercialization and achieving payer acceptance.
Top Insights
NEURO PMR study validated Swoop's clinical viability with 92% diagnostic concordance to standard MRI and 4x higher patient preference across comfort and anxiety metrics
Jefferson Abington Hospital study demonstrated $590 average cost savings per patient and 18-hour reduction in MRI wait times, establishing economic value proposition
Record Q4 placements with next-generation Swoop launch, CE Mark and UKCA approvals, raising $20.1M in October 2025, and Q4 revenue guidance of $5-6M
Valuation assumes rapid adoption and pricing power but remains vulnerable to competitive innovation, regulatory headwinds, and payer acceptance delays
Named Competitors
MRI Systems — Conventional high-field MRI systems with established clinical infrastructure
MRI Systems — Full-spectrum clinical imaging including traditional MRI platforms
Portable Imaging Systems — Portable ultrasound and point-of-care imaging alternative
Recent Developments
(December 2025) FDA clearance for Optive AI multi-direction DWI imaging software for improved stroke detection
(December 2025) India regulatory approval from CDSCO; partnership with Radiosurgery Global for commercial launch
(January 2026) NEURO PMR study results published demonstrating 92% diagnostic concordance and superior patient experience